Drug Treatment Response Assay
Drug Treatment Response Assay - Related Videos
04:15
Brain Tumor Stem Cell (BTSC) Migration Assay for Drug Treatment Studies: An In Vitro Live-cell Imaging Technique to Analyze the Effect of Drug Treatment on Migration of BTSCs
0 Views •
2025
In this video, we perform brain tumor stem cell migration assay to analyze the effect of the drug of interest on the migration of live brain tumor stem cells using chemotaxis migration plate. Live-cell imaging facilitates the visualization and quantification of cell migration during the assay.
09:42
Comprehensive Analysis of Drug Response using the FLICK Assay
0 Views •
Cited by 1 •
2025
This protocol describes how to use the FLICK assay for evaluating drug responses, including detailed instructions for using this assay to compute the drug-induced growth rates and death rates and to evaluate the mechanism of drug-induced cell death.
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
0 Views •
Cited by 121 •
2017
This protocol describes an assay for measuring CFTR function and CFTR modulator responses in cultured tissue from subjects with cystic fibrosis (CF). Biopsy-derived intestinal organoids swell in a cAMP-driven fashion, a response that is defective (or strongly reduced) in CF organoids and can be restored by exposure to CFTR modulators.
03:40
Generation of Microtumors: An In Vitro Culture Technique to Culture 3D Microtumors to Analyze Response to Drug Treatment
0 Views •
2025
In this video, we generate microtumors from patient-derived tumor cells using 3D human biogel. These microtumors closely resemble the in vivo tumor microenvironment and serve as potential platforms for drug testing.
11:12
Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs
0 Views •
Cited by 359 •
2013
A hemolysis assay can be used as a rapid, high-throughput screen of drug delivery systems' cytocompatibility and endosomolytic activity for intracellular cargo delivery. The assay measures the disruption of erythrocyte membranes as a function of environmental pH.
FAQs
They establish controlled treatment conditions for comparing cellular or patient-derived responses. Applying defined concentrations and assessing samples after a specified period allows researchers to relate observed changes to drug amount and exposure duration. Varying concentration also supports construction of a dose-response profile, while consistent timing improves comparisons across samples and experimental conditions.
These readouts capture different consequences of treatment. Viability measures changes in the number or state of living cells, proliferation reflects changes in cell growth, apoptosis indicates programmed cell death, and molecular biomarkers reveal treatment-associated biological changes. Selecting one or more endpoints helps researchers characterize response beyond a single measurement and connect outcomes with treatment effects.
A dose-response profile shows how a sample changes across multiple drug concentrations rather than at only one exposure level. Comparing the pattern among samples can reveal differences in treatment response. If a sample shows limited measurable change across the tested conditions, the result can help characterize resistance, whereas larger changes indicate a stronger observed response to the compound.
Comparing samples reveals whether a compound produces similar or differing effects in distinct biological contexts. Researchers can examine changes in viability, proliferation, apoptosis, or molecular biomarkers under matched treatment conditions. These comparisons help identify response patterns, investigate why treatments succeed or fail, and determine whether a therapy may be more useful for particular samples.
The workflow begins with selecting cells, tissues, or patient-derived samples and exposing them to defined concentrations of a therapeutic compound. Samples remain under treatment for a specified period, after which researchers quantify selected response measures, such as viability, proliferation, apoptosis, or molecular biomarkers. The measurements are then organized into a dose-response profile for comparison and interpretation.
These assays support several stages of therapeutic research. During drug development, they help characterize how effectively a compound affects biological samples. They can also contribute to toxicity assessment by measuring treatment-associated changes and support investigations into why treatments succeed or fail. Their results provide experimental evidence for comparing compounds, conditions, or sample-specific responses.
By testing therapeutic compounds across patient-derived samples, researchers can compare response patterns between individuals or sample groups. Measurements of viability, proliferation, apoptosis, and molecular biomarkers help identify differences associated with treatment outcome. This information can support selection of therapies most likely to benefit particular patients, while also highlighting samples that may show limited response or resistance.